Monitoring minimal residual disease (MRD) in patients with acute lymphoblastic leukemia (ALL) is a useful way for assessing treatment response and relapse.
We studied the value of MRD and showed a correlation with relapse for 34 adult patients with ALL. MRD was evaluated by real-time quantitative polymerase chain reaction (RQ-PCR) with probes derived from fusion chimeric genes (BCR/ABL) (n=12)
or PCR-based detection of clonal immunoglobulin and T-cell receptor gene rearrangements (n=16), or both (n=6). We analyzed 27 of the 34 patients who could be examined for MRD on day 100 after induction therapy. The overall survival (OS) rate (45.0%) and relapse-free survival (RFS) rate (40.0%) at 2 years in CR patients with MRD level 10 -3 (n=12) were significantly lower than those in CR patients with MRD
The prognosis of adult patients with acute lymphoblastic leukemia (ALL) is dismal.
Although most adult patients with ALL enter complete remission (CR), only 30% to 40% of patients survive 5 or more years (1) . The major cause of treatment failure is relapse, affecting approximately half of the patients who have achieved CR (2) . Survival depends on risk factors such as age, white blood cell (WBC) count, time to CR, disease immunophenotype, cytogenetics, and molecular abnormalities (1) , and several studies have shown that detection of minimal residual disease (MRD) in childhood and adult ALL is an independent risk parameter of high clinical relevance (3) . Early indicators of disease outcome would be particularly useful for the design of new treatments.
The rationale of MRD analysis is to improve estimation of treatment response, to provide independent prognostic information, and to optimize therapeutic strategies.
Established methods for detecting MRD are polymerase chain reaction (PCR) amplification of antigen receptor genes and of fusion transcripts and flow cytometric detection of ectopic or aberrant immunophenotypes (4).
Flow cytometric detection of MRD is based on the identification of immunophenotypic combinations expressed on leukemic cells but not on normal hematopoietic cells (4). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 transcripts are suitable for MRD detection; however, they cannot be identified in all patients. Therefore, the complementary use of both methods might allow monitoring of virtually all patients for MRD.
We previously reported that molecular MRD status by PCR amplification of antigen receptor genes is a strong predictor of outcome in adult ALL (5) . In this study, we accumulated more patients and reevaluated the significance of MRD. We also compared the two methods of MRD detection: PCR amplification and flow cytometry. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 these fusion transcripts were not used to detect MRD. Eighteen (52.9%) of the 34 patients received chemotherapy only, and the remaining 16 (47.1%) received allogeneic stem cell transplantation after chemotherapy. Eight patients had related donors and 8 patients had unrelated donors. Clinical characteristics of the patients are shown in Table   2 .
Twenty-six patients were treated with intravenous cyclophosphamide, vincristine, daunorubicin or doxorubicin, etoposide, cytosine arabinoside, steroid, l-asparaginase, with or without imatinib, and intrathecal methotrexate for induction therapy. One patient received only imatinib, another patient received etoposide and imatinib, and another patient was treated with idarubicin and cytosine arabinoside because the diagnosis of acute myelogenous leukemia was made at the first time. The induction therapies for other five patients were not known. The conditioning regimen for allogeneic transplantation consisted of total body irradiation in combination with cyclophosphamide and etoposide for 13 patients or fludarabine for 1 patient. The conditioning regimen was unknown for the other three patients.
Clinical decisions concerning treatment of the patients were made by their physicians regardless of MRD results. Enrollment in the study was contingent upon informed consent of the patient. The study was approved by the Institutional Review Board of Hokkaido University Graduate School of Medicine.
Remission and relapse
Morphologic CR was defined as less than 5% blast cells in a regenerated bone marrow (BM) aspirate, absence of extramedullary leukemia, and peripheral blood (PB) neutrophil and platelet counts of > 1.5 x 10 9 /L and > 100 x 10 9 /L, respectively. Clinical relapse was defined as detection of at least 5% blast cells in BM or detection of leukemic cells extramedullary.
Sample processing
BM or PB was collected at the time of initial diagnosis and at several clinical points (day , before the conditioning regimen, after transplantation and any points at the end of each chemotherapy). Some samples were collected after completion of the treatment. The samples were used for PCR study of IGH/TCR rearrangements and BCR/ABL fusion gene transcripts. Some of the samples were also used for flow cytometry study. A total of 231 samples (220 BM and 11 PB samples) were analyzed; the median number of samples analyzed per patient was 6 (range, 2-22) ( Table 3 ). For a total of 27 BM samples from five patients MRD was analyzed by both PCR amplification and flow cytometry. We did not evaluate the 
PCR analysis of IGH/TCR gene rearrangements
When a BCR/ABL chimeric fusion gene was not present, leukemia-specific probes were generated by genomic amplification and sequencing of VDJ regions of the immunoglobulin heavy chain (IGH) and T-cell receptor  and  (TCR and TCR)
genes. The method of PCR analysis of IGH/TCR gene rearrangements has been described previously (5) . The sensitivity was 10 -3 . When two MRD probes gave different results in the same patient, the higher MRD level was considered valid for the purpose of the study.
Flow cytometry
Leukemia-associated immunophenotypes were identified by flow cytometry with four-color combinations of monoclonal antibodies. The flow cytometric method used has been described previously (6). For each case, one or more marker combinations that 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 allowed the identification of one leukemic cell in 10 3 -10 4 normal nucleated cells were selected at diagnosis and used to study MRD during therapy. This approach reached sensitivities up to 10 -4 .
Survival curves were plotted according to the method of Kaplan and Meier, and comparison of the curves was made using log-rank tests. Overall survival (OS) was measured from the date of induction therapy until death. Relapse-free survival (RFS)
was measured from the date of induction therapy until the date of relapse or death, whichever occurred first. Univariate and multivariate analyses were performed to evaluate the independent prognostic factors for OS and RFS by a Cox regression model. 
Results

Identification of MRD-PCR targets
Eighteen patients were Ph chromosome-positive and their MRD was detected by BCR/ABL fusion transcripts. Thirty IGH/TCR gene rearrangements were found at diagnosis in the 22 ALL patients: 19 IGH (two different kinds in five patients), 6 TCR, and 5 TCR gene rearrangements. Eight patients had two targets and 14 patients had one target (Table 3) We analyzed 27 of the 34 patients who could be examined for MRD on day 100. The overall survival (OS) rate (45.0%) and relapse-free survival (RFS) rate (40.0%) at 2 years in CR patients with MRD level 10 -3 (n=12) were significantly lower than those in CR patients with MRD level <10 -3 (n=15) (OS rate: 79.0%, RFS rate: 79.4%) (log-rank test, P=0.017 and 0.0007). A lower MRD value on day 100 after induction therapy was associated significantly with longer survival (Fig.1a and b) . Two patients were excluded from the study because of relapse before day 100 after induction therapy.
Monitoring of MRD enabled prediction of relapse in 10 of the 14 relapsed patients whose results of MRD analyses were available before relapse. The median time from molecular to clinical relapse was 65 days (range, 12-305 days).
Comparison of the results obtained by flow cytometry and PCR analysis
We compared MRD levels determined by both flow cytometry and PCR analysis in 27
follow-up BM samples from 5 patients ( Table 4) Of the 10 samples that were MRD-positive by flow cytometry but MRD-negative by 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 from 2 patients. The other 5 samples from 3 patients were MRD-positive by flow cytometry (0.18%, 0.16%, 0.39%, 0.42%, and 2.53%) but MRD-negative by PCR.
Other prognostic factors
In addition, we examined factors correlated with OS and RFS by the log-rank test. In the log-lank test, a lower MRD value on day 100 was associated significantly with longer survival (Table 5 ). However, we could not determine other factors, such as age, WBC count at diagnosis, Ph chromosome, immunophenotype, sex, days to achieve CR, and type of treatment (chemotherapy or transplantation). Therefore, our data provide evidence that molecular MRD status on day 100 is a strong predictor of outcome in adult ALL.
Relative risk of relapse
Looking for informative predictors of the achievement of molecular CR on day 100, we used univariate and multivariate analyses to investigate the role of conventional clinical findings such as age younger than 55 years or not, WBC count at diagnosis, Ph chromosome, immunophenotype, sex, days to achieve CR, and MRD levels on day 30.
Univariate analysis showed that MRD positivity on day 100 was associated with age older than 55 years and MRD positivity on day 30, but there were no significant associations in multivariate analysis. 8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 65
Discussion
There is increasing evidence that MRD has strong prognostic significance in adult patients with ALL. Mortuza et al. found that MRD positivity detected especially at 3 to 6 months after induction therapy in adults with B-ALL was associated with an increased risk of relapse (7). Holowiecki et al. reported that MRD equal or greater than 0.1% of bone marrow cells after induction was a strong and independent predictor for relapse in both standard and high-risk groups (2).
We also showed that OS and RFS at 2 years in CR patients positive for MRD by PCR-based detection of BCR/ABL transcripts or IGH/TCR gene rearrangements were significantly lower than those in CR patients negative for MRD.
Three highly specific and sensitive methodologies for MRD detection are available: PCR-based detection of rearranged IGH/TCR genes is currently the most broadly applied MRD technique owing to its high level of standardization, its well-defined quantitative range and good sensitivity, as well as applicability in the majority of ALL 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 patients (3). To reach a higher level of sensitivity, DNA sequencing of the junctional regions is required in order to design tumor-specific primers and/or probes.
A major drawback of using rearranged immune genes as MRD-PCR targets is the possible occurrence of continuing rearrangements during the course of therapy and during follow-up, which can lead to false-negative PCR results (9).
Relapse could not be predicted in 4 of the 14 relapsed patients in this study. In two of them, TCR or IGH gene rearrangement was not detected even at the time of relapse.
Clonal TCR rearrangement in particular can be lost during the follow-up period preceding relapse (10), and continuing rearrangements during the disease course occur in 10-40% of cases depending on the target used (11).
One specific advantage of flow cytometry over PCR-based assays is that it allows direct quantification of MRD, rather than extrapolating it from amounts of PCR product (9).
However, the immunophenotype of leukemic cells may change during progression of the disease, and if these changes affect markers used for monitoring MRD, a false-negative finding may result (12, 13) .
In this study, concordance between the flow cytometric and PCR results was obtained in 17 (63.0%) of the 27 samples. Comparative analyses showed that more concordant results could be obtained for both methods at the level of 10 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 cases, some samples showed discordant results. In these cases, MRD might be overestimated by flow cytometry because normal cells cannot be easily distinguished from leukemic cells in studies of MRD (6).
The combination use of the two methods may offset the possibility of false-negative and false-positive MRD results due to these events (16).
We did not find a significant prognostic value of MRD in patients who received allogeneic transplantation. It has been shown that MRD detected before transplantation was a significant predictor of failure after transplantation (17, 18). However, Patel et al.
suggested that It has also been shown that MRD status after allogeneic transplantation was an important predictor of outcome in adults with ALL (7, 18). The MRD status before and after transplantation was not correlated with survival in this study, which may be explained by the small number of patients who received transplantation.
Results of log-rank tests showed that age, WBC count at diagnosis, sex, Ph-positivity, and immunophenotype were not associated with prognosis or relapse. Generally, advanced age of the patient and high WBC count at diagnosis with acute leukemia are related to poor prognosis. In this study, we did not intervene in clinical decisions   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 concerning treatment of the patients, but MRD level on day 100 after induction chemotherapy was only a good prognostic factor to monitor relapse and classify the groups as good or poor prognosis.
Although limitation of MRD assessment for prediction of extramedullary relapse is Further progress in how to assess MRD and improve the prognosis in adult patients with ALL in association with MRD is expected.
In this study, we investigated the prognostic value of MRD in adult patients with ALL.
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Figure legends TdT/CD10/CD34/CD19 Table   Table 5 . Univariate and multivariate analyses of prognostic factors associated with overall survival and relapse-free survival (log-rank test). 
